Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines).
Simkova
Vladislava
V
Sektion Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum, Parkstrasse 11, D-89073 Ulm, Germany.
Radermacher
Peter
P
Barth
Eberhard
E
D002303:Cardiac Output, Low / Q000188:drug therapy; D002316:Cardiotonic Agents / Q000494:pharmacology; D004734:Energy Metabolism / Q000187:drug effects*; D006801:Humans; D020105:Milrinone / Q000627:therapeutic use; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000494:pharmacology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D002316:Cardiotonic Agents; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D020105:Milrinone